You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Insulet (PODD) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Read MoreHide Full Article
Insulet (PODD - Free Report) reported $509.8 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 37.9%. EPS of $1.40 for the same period compares to $0.55 a year ago.
The reported revenue represents a surprise of +10.79% over the Zacks Consensus Estimate of $460.17 million. With the consensus EPS estimate being $0.67, the EPS surprise was +108.96%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Insulet performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenue- International Omnipod: $106.40 million compared to the $98.16 million average estimate based on seven analysts. The reported number represents a change of +18% year over year.
Revenue- U.S. Omnipod: $394.60 million versus the seven-analyst average estimate of $358.10 million. The reported number represents a year-over-year change of +42.9%.
Revenue- Total Omnipod: $501 million compared to the $456.29 million average estimate based on seven analysts. The reported number represents a change of +36.7% year over year.
Revenue- Drug Delivery: $8.80 million versus the seven-analyst average estimate of $3.76 million. The reported number represents a year-over-year change of +166.7%.
Shares of Insulet have returned -4.3% over the past month versus the Zacks S&P 500 composite's +3.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Insulet (PODD) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Insulet (PODD - Free Report) reported $509.8 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 37.9%. EPS of $1.40 for the same period compares to $0.55 a year ago.
The reported revenue represents a surprise of +10.79% over the Zacks Consensus Estimate of $460.17 million. With the consensus EPS estimate being $0.67, the EPS surprise was +108.96%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Insulet performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- International Omnipod: $106.40 million compared to the $98.16 million average estimate based on seven analysts. The reported number represents a change of +18% year over year.
- Revenue- U.S. Omnipod: $394.60 million versus the seven-analyst average estimate of $358.10 million. The reported number represents a year-over-year change of +42.9%.
- Revenue- Total Omnipod: $501 million compared to the $456.29 million average estimate based on seven analysts. The reported number represents a change of +36.7% year over year.
- Revenue- Drug Delivery: $8.80 million versus the seven-analyst average estimate of $3.76 million. The reported number represents a year-over-year change of +166.7%.
View all Key Company Metrics for Insulet here>>>Shares of Insulet have returned -4.3% over the past month versus the Zacks S&P 500 composite's +3.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.